Latest Breaking News On - For global - Page 4 : comparemela.com

Junshi Biosciences Announces JAMA Publication of Results from NEOTORCH, a Randomized Phase 3 Trial of Perioperative Toripalimab plus Chemotherapy for Patients with Resectable Non-Small Cell Lung Cancer

SHANGHAI, China, Jan. 17, 2024 (GLOBE NEWSWIRE) Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading…

New yorkUnited statesUnited kingdomSan franciscoBarbara shecterTiff macklemJunshi biosciencesZhi liJoe oconnorGabriel friedmanPerioperative toripalimabAmerican society of clinical oncologyAustralia therapeutic goods administrationEuropean medicines agencyShanghai junshi biosciences co ltdNational post

Junshi Biosciences Announces JAMA Publication of Results from NEOTORCH, a Randomized Phase 3 Trial of Perioperative Toripalimab plus Chemotherapy for Patients with Resectable Non-Small Cell Lung Cance

Junshi Biosciences Announces JAMA Publication of Results from NEOTORCH, a Randomized Phase 3 Trial of Perioperative Toripalimab plus Chemotherapy for Patients with Resectable Non-Small Cell Lung Cance
finanzen.ch - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.ch Daily Mail and Mail on Sunday newspapers.

San franciscoUnited statesUnited kingdomZhi liJunshi biosciencesPr teamAmerican society of clinical oncologyShanghai junshi biosciences co ltdAustralia therapeutic goods administrationNational reimbursement drug listIr teamRegulatory agencyJournal of the american medical associationDrug administrationShanghai jiaotong universityEuropean medicines agency

Junshi Biosciences Announces Publication of Results from TORCHLIGHT, a Randomized Phase 3 Trial of Toripalimab for the Treatment of Metastatic or Recurrent Triple-negative Breast Cancer in Nature Medi

Junshi Biosciences Announces Publication of Results from TORCHLIGHT, a Randomized Phase 3 Trial of Toripalimab for the Treatment of Metastatic or Recurrent Triple-negative Breast Cancer in Nature Medi
finanzen.ch - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.ch Daily Mail and Mail on Sunday newspapers.

United statesSan franciscoUnited kingdomJunshi biosciencesZhi liAustralia therapeutic goods administrationIr teamDrug administrationChinese society of clinical oncologyRegulatory agencyShanghai junshi biosciences co ltdNational medical products administrationEuropean medicines agencyPr teamNational reimbursement drug listGlobal research

Junshi Biosciences Announces Publication of Results from TORCHLIGHT, a Randomized Phase 3 Trial of Toripalimab for the Treatment of Metastatic or Recurrent Triple-negative Breast Cancer in Nature Medicine

Junshi Biosciences Announces Publication of Results from TORCHLIGHT, a Randomized Phase 3 Trial of Toripalimab for the Treatment of Metastatic or Recurrent Triple-negative Breast Cancer in Nature Medicine
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

San franciscoUnited statesUnited kingdomJunshi biosciencesZhi liRegulatory agencyDrug administrationAustralia therapeutic goods administrationChinese society of clinical oncologyNational reimbursement drug listNational medical products administrationShanghai junshi biosciences co ltdEuropean medicines agencyIr teamGlobal researchPr team

Junshi Biosciences Announces Approval of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Resectable NSCLC Patients

SHANGHAI, China, Jan. 02, 2024 Shanghai Junshi Biosciences Co., Ltd , a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of.

United kingdomSan franciscoUnited statesJunshi biosciencesZhi liShanghai junshi biosciences co ltdWorld health organizationDrug administrationPr teamNational reimbursement drug listAmerican society of clinical oncologyAustralia therapeutic goods administrationNational medical products administrationIr teamRegulatory agencyEuropean medicines agency